Recent News

• 03.31.2025 - LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
• 03.27.2025 - LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
• 03.10.2025 - New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
• 02.25.2025 - LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
• 02.13.2025 - LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Recent Filings

• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report
• 03.24.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.14.2025 - 8-K Current report
• 03.11.2025 - 8-K Current report
• 03.11.2025 - 8-K Current report
• 03.11.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 8-K Current report